Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

Citation

  • Authors: Krzywinska, E., Kantari-Mimoun, C., Kerdiles, Y., Sobecki, M., Isagawa, T., Gotthardt, D., Castells, M., Haubold, J., Millien, C., Viel, T., Tavitian, B., Takeda, N., Fandrey, J., Vivier, E., Sexl, V., Stockmann, C.
  • Year: 2017
  • Journal: Nat Commun 8 1597
  • Applications: in vivo / DNA / in vivo-jetPEI

Method

For in vivo administration, FLT1 and ctrl plasmid DNA was complexed with in vivo-jetPEI. 15 μg of DNA per one injection was complexed with in vivo-JetPEI at an N/P ratio of 6 in 5% glucose solution for intratumoural injection. The mixture was incubated for at least 30 min at room temperature. Randomised cohorts of the tumour-bearing WT and HIF-1α KO mice received intratumoural injections of 15 μg of DNA in 100 μl of 5% glucose solution every 2 days starting on day 6 until endpoint at day 14. Control mice were injected with control plasmid.

Abstract

Productive angiogenesis, a prerequisite for tumour growth, depends on the balanced release of angiogenic and angiostatic factors by different cell types within hypoxic tumours. Natural killer (NK) cells kill cancer cells and infiltrate hypoxic tumour areas. Cellular adaptation to low oxygen is mediated by Hypoxia-inducible factors (HIFs). We found that deletion of HIF-1alpha in NK cells inhibited tumour growth despite impaired tumour cell killing. Tumours developing in these conditions were characterised by a high-density network of immature vessels, severe haemorrhage, increased hypoxia, and facilitated metastasis due to non-productive angiogenesis. Loss of HIF-1alpha in NK cells increased the bioavailability of the major angiogenic cytokine vascular endothelial growth factor (VEGF) by decreasing the infiltration of NK cells that express angiostatic soluble VEGFR-1. In summary, this identifies the hypoxic response in NK cells as an inhibitor of VEGF-driven angiogenesis, yet, this promotes tumour growth by allowing the formation of functionally improved vessels.

Go to